İnvaziv Ürotelyal Karsinom

Epstein JI, ReuterVE, Amin MB. Çeviri ed. Prof.Dr.DilekErtoy Baydar Mesane Biyopsilerinin Yorumu. Nobel Tıp Kitabevleri,İstanbul.2016).

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, TrottiA,editors. AJCC cancerstagingmanual (7th ed). New York, NY: Springer; 2010.

Amin M, Edge SB, Greene FL, et al.AJCCCancerStaging Manual, 8th ed. New York, NY: Springer; 2017: Chapter 62: UrinaryBladder. 765–773.

Cheng L, MacLennan GT, Lopez-Beltran A. Histologicgrading of urothelialcarcinoma: a reappraisal. Hum Pathol. 2012; 43:2097–2108.

Cheng L, Neumann RM, Nehra A, et al. Cancerheterogeneityanditsbiologicimplications in thegrading of urothelialcarcinoma. Cancer.2000;88:1663–1670.

Cheng L, Bostwick DG. World HealthOrganizationand International Society of UrologicalPathologyclassificationandtwo-numbergradingsystem of bladdertumors: reply. Cancer. 2000; 88:1513–1516.

MacLennan GT, Kirkali Z, Cheng L. Histologicgrading of noninvasivepapillaryurothelialneoplasms. EurUrol. 2007; 51:889–897; discussion 97-8.

Cheng L, Montironi R, Davidson DD, et al. Stagingandreporting of urothelialcarcinoma of theurinarybladder. ModPathol. 2009;22(Suppl 2): S70–S95.

Moch H, Humprey PA, UlbrightTM, Reuter VE, eds.. World HealthOrganizationClassification of Tumors. oftheUrinarySystemand Male GenitalOrgans. 4th ed. Lyon, France: IARC Press; 2016. World HealthorganizationClassification of Tumours; vol 8.

Lopez-Beltran A, Cheng L. Stage pT1 bladdercarcinoma: diagnosticcriteria, pitfallsandprognosticsignificance. Pathology. 2003; 35:484–491.

Cheng, L, MacLennan, GT Bostwick, DG. (2020). Urologicsurgicalpathology (Fourthedition.). Philadelphia, PA: Elsevier.

Jimenez RE, Keany TE, Hardy HT, et al. pT1 urothelialcarcinoma of thebladder: criteriafordiagnosis, pitfalls, andclionicalimplications. AdvAnatPathol. 2000;7:13–25.

Tamas EF, Epstein JI. Detection of residualtumorcells in bladderbiopsyspecimens: pitfalls in theinterpretation of cytokeratinstains. Am J SurgPathol. 2007;31:390–397.

Paner GP, Shen SS, Lapetino S, et al. Diagnosticutility of antibodytosmoothelin in thedistinction of muscularispropriafrommuscularismucosae of theurinarybladder: a potentialancillarytool in thepathologicstaging of invasiveurothelialcarcinoma. Am J SurgPathol. 2009;33:91–98.

Council L, Hameed O. Differentialexpression of immunohistochemicalmarkers in bladdersmoothmuscleandmyofibroblasts, andthepotentialutility of desmin, smoothelin, andvimentin in staging of bladdercarcinoma. ModPathol. 2009; 22:639–650.

Philip AT, Amin MB, Tamboli P, Lee TJ, Hill CE, Ro JY. Intravesicaladiposetissue: a quantitativestudy of its presence andlocationwithimplicationsfortherapyandprognosis. Am J SurgPathol. 2000 Sep;24(9):1286-90.

Drew PA, Furman J, Civantos F, Murphy WM. Thenestedvariant of transitionalcellcarcinoma: an agressiveneoplasmwithinnocuoushistology. ModPathol. 1996;9(10): 989-94.

Shariat SF, Palapattu GS, Karakiewicz PI., Concomitantcarcinoma in situ is a feature of aggressivedisease in patientswith organ-confinedTCC at radicalcystectomy. EurUrol. Jan 2007;51(1):152–160.

vanRhijn BW, Burger M, Lotan Y. Recurrenceandprogression of disease in non-muscle-invasivebladdercancer: fromepidemiologytotreatmentstrategy. EurUrol. Sep 2009;56(3):430–442.

Brimo F, Wu C, Zeizafoun N.2Prognosticfactors in T1 bladderurothelialcarcinoma: thevalue of recordingmillimetricdepth of invasion, diameter of invasivecarcinoma, andmuscularismucosainvasion. Human pathology. Jan 2013;44(1):95–102.

Idrees MT, Alexander RE, Kum JB, et al. Thespectrum of histopathologicfindings in vesicaldiverticulum: implicationsforpathogenesisandstaging. Hum Pathol. 2013;44:1223–1232

Tilki D, Svatek RS, Karakiewicz PI, et al. pT3 Substaging is a prognosticindicatorforlymphnodenegativeurothelialcarcinoma of thebladder. J Urol. 2010;184:470–474.

Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratificatio of pathologicalstage T3N0 bladdercancerafterradicalcystectomy. J Urol. 2011;185:1216–1220.

Cheng L, Weaver AL, Bostwick DG. Predictingextravesicalextension of bladdercarcinoma: a novelmethodbased on micrometermeasurement of thedepth of invasion in transurethralresectionspecimens. Urology. 2000;55:668–672.

Paner GP, Stadler WM, HanselDE,Montironi R, Lin DW, Amin MB. Updates in theeighthedition of thetumor-node-metastasisstagingclassificationforurologiccancers. EurUrol. 2018;73(4):560–569.

Paner GP, Montironi R, Amin MB. Challenges in PathologicStaging of BladderCancer: ProposalsforFreshApproaches of AssessingPathologicStage in Light of RecentStudiesandObservationsPertainingtoBladderHistoanatomicVariances. AdvAnatPathol2017;24:113-127.

Patel AR, Cohn JA, Abd El Latif A, et al. Validation of new AJCC exclusioncriteriaforsubepithelialprostaticstromalinvasionfrom pT4a bladderurothelialcarcinoma. J Urol2013;189:53–8.

Cornejo KM, Rice-Stitt T, Wu CL. Updates in StagingandReporting of GenitourinaryMalignancies. ArchPatholLabMed. 2020 Mar;144(3):305-319.